The Amyotrophic Lateral Sclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Amyotrophic Lateral Sclerosis pipeline products will significantly revolutionize the Amyotrophic Lateral Sclerosis market dynamics.
DelveInsight’s “Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Amyotrophic Lateral Sclerosis, historical and forecasted epidemiology as well as the Amyotrophic Lateral Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Amyotrophic Lateral Sclerosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Amyotrophic Lateral Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Amyotrophic Lateral Sclerosis Market Insights
Amyotrophic Lateral Sclerosis Overview
Amyotrophic lateral sclerosis (ALS) is one of a group of disorders known as motor neuron diseases. It is characterized by the progressive degeneration and eventual death of nerve cells (motor neurons) in the brain and spinal cord that facilitate communication between the nervous system and voluntary muscles of the body. ALS affects both the upper and lower motor neurons, so that the transmission of messages is interrupted.
Some of the key facts of the Amyotrophic Lateral Sclerosis Market Report:
- The Amyotrophic Lateral Sclerosis market size was valued at USD 490 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The total diagnosed cases of Amyotrophic Lateral Sclerosis was 59,130 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032
- In the United States, in 2021, the proportion of male and female cases were 14,948 and 10,869 respectively
- Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Alector,GSK, NeuroSense Therapeutics, Biogen, Ionis,Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Therapeutics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals
- Key Amyotrophic Lateral Sclerosis Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, RELYVRIO (AMX0035), Exservan, TIGLUTIK, TEGLUTIK, Nuedexta, and others
Get a Free sample for the Amyotrophic Lateral Sclerosis Market Report
Key benefits of the Amyotrophic Lateral Sclerosis Market report:
- Amyotrophic Lateral Sclerosis market report covers a descriptive overview and comprehensive insight of the Amyotrophic Lateral Sclerosis Epidemiology and Amyotrophic Lateral Sclerosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Amyotrophic Lateral Sclerosis market report provides insights on the current and emerging therapies.
- Amyotrophic Lateral Sclerosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Amyotrophic Lateral Sclerosis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Amyotrophic Lateral Sclerosis market.
Amyotrophic Lateral Sclerosis Market
The dynamics of the Amyotrophic Lateral Sclerosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“According to the estimates, the highest market size of ALS was found in the United States and the least was in Spain across the 7MM. Besides, the upcoming therapies of ALS are expected to combat the current unmet needs faced by the patients with ALS and add to the overall growth of the ALS market size.”
Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiological Insights
Amyotrophic Lateral Sclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Amyotrophic Lateral Sclerosis Epidemiology Segmentation:
The Amyotrophic Lateral Sclerosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Amyotrophic Lateral Sclerosis
- Prevalent Cases of Amyotrophic Lateral Sclerosis by severity
- Gender-specific Prevalence of Amyotrophic Lateral Sclerosis
- Diagnosed Cases of Episodic and Chronic Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to get launched during the study period. The analysis covers Amyotrophic Lateral Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Amyotrophic Lateral Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis market share @ Amyotrophic Lateral Sclerosis market forecast
Amyotrophic Lateral Sclerosis Therapies and Key Companies
- AS-202: Acurastem
- HK001: Everfront Biotech Co., Ltd
- Tegoprubart: Eledon Pharmaceuticals
- AP-101: AL-S Pharma
- BLZ945: Novartis
- ANX005: Annexon Biosciences
- MN-166: MediciNova
- TW001: Treeway
- BIIB067: Biogen
Amyotrophic Lateral Sclerosis Market Drivers
- Availability of Epidemiological Data
- Robust Pipeline Activity
- Increasing Awareness Programs
Scope of the Amyotrophic Lateral Sclerosis Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Alector,GSK, NeuroSense Therapeutics, Biogen, Ionis,Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, and others
- Key Amyotrophic Lateral Sclerosis Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, RELYVRIO (AMX0035), Exservan, TIGLUTIK, TEGLUTIK, Nuedexta, and others
- Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
- Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Amyotrophic Lateral Sclerosis Unmet Needs, KOL’s views, Analyst’s views, Amyotrophic Lateral Sclerosis Market Access and Reimbursement
Amyotrophic Lateral Sclerosis Market Barriers
- High Medical Cost
- Lack of Proper Diagnosis
- High Mortality Rate
- No cure, only delaying progression
Table of Contents
- Amyotrophic Lateral Sclerosis Market Report Introduction
- Executive Summary for Amyotrophic Lateral Sclerosis
- SWOT analysis of Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis Patient Share (%) Overview at a Glance
- Amyotrophic Lateral Sclerosis Market Overview at a Glance
- Amyotrophic Lateral Sclerosis Disease Background and Overview
- Amyotrophic Lateral Sclerosis Epidemiology and Patient Population
- Country-Specific Patient Population of Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis Current Treatment and Medical Practices
- Amyotrophic Lateral Sclerosis Unmet Needs
- Amyotrophic Lateral Sclerosis Emerging Therapies
- Amyotrophic Lateral Sclerosis Market Outlook
- Country-Wise Amyotrophic Lateral Sclerosis Market Analysis (2019–2032)
- Amyotrophic Lateral Sclerosis Market Access and Reimbursement of Therapies
- Amyotrophic Lateral Sclerosis Market Drivers
- Amyotrophic Lateral Sclerosis Market Barriers
- Amyotrophic Lateral Sclerosis Appendix
- Amyotrophic Lateral Sclerosis Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
To know more about Amyotrophic Lateral Sclerosis treatment, visit @ Amyotrophic Lateral Sclerosis Medications
Related Reports:
Amyotrophic Lateral Sclerosis Pipeline
“Amyotrophic Lateral Sclerosis Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Amyotrophic Lateral Sclerosis market. A detailed picture of the Amyotrophic Lateral Sclerosis pipeline landscape is provided, which includes the disease overview and Amyotrophic Lateral Sclerosis treatment guidelines.
Amyotrophic Lateral Sclerosis Epidemiology
DelveInsight’s ‘Amyotrophic Lateral Sclerosis Epidemiology Forecast to 2032‘ report delivers an in-depth understanding of the disease, historical and forecasted Amyotrophic Lateral Sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com